



International Dating
Rencontres Internationales Recherche
— 2018 —

International R&D Dating “Immuno-Oncology”

February 6th 2018

Paris



International R&D Dating “Immuno-Oncology”

February 6th 2018

Public and private partnerships are essential to foster innovation in health industries. Since its first edition in 2009, the **International R&D Dating** gathers the excellence of academic research and the world R&D decision-makers of the health industries in order to foster partnerships. This event is organized by **ARIIS**, Alliance for Research and Innovation in Health Industries, and by **Aviesan**, French National Alliance for Life Sciences and Health. This day is a unique moment for exchanges, it’s an opportunity for public authorities, academics researchers and industrials to meet each other. Furthermore, the participation of world decision-makers provide international visibility to the event.

Topics at the heart of innovation issues

Every edition focuses on a specific theme (Neurology, Cancerology, Metabolic diseases, Rare diseases, ...). This choice allows to gather, during one day, public and private communities specialized in this field: it is **a laboratory of new ideas and innovations for medicine of tomorrow**. This day is thus a means to build bridges between academic and industrial world in order to develop partnership research and to highlight the attractiveness of French research at an international level.

New edition on the thematic of “Immuno-Oncology”

The next edition, on the topic of **Immuno-Oncology**, will be held on **February, 6th 2018** in collaboration with ITMO Cancer (Multi-Organization Thematic Institute Cancer) of Aviesan.

In the morning, the format will be renewed with public-private debates, “Elevator pitches” on innovative projects and highlight on new ways to innovate. The afternoon will be the opportunity to have face-to-face meetings between academics and industrials.



Description of the topic

Considered by the ASCO (American Society of Clinical Oncology) as “the clinical advance of year 2017”, the immuno-oncology has become part of the **therapeutic arsenal used facing advanced cancers or recurrences**. Yesterday on the prostate and the melanoma, these treatments are more and more effective against other cancers: lymphoma of Hodgkin, kidney, lung and even certain hematological cancers.

In this domain, the oldest of the sectors of innovation concerns the **targets of inhibition of control points**, among which some are used in clinic. The mechanisms of signaling sent (CTLA-4 and PD-1/PD-L1, and more recently TIM3, GITR and LAG3) seem effective, even in the face of the hypermutability and the tumoral heterogeneousness. However, numerous questions remain: toxicity, stratification of patients, inhibitors' combination, addition of other therapies, etc. That is why, at the same time, the innovations in the field of the **immunomodulation** are of a big interest: interleukine-2 (in particular IL-10, IL-15, IL-17 and IL-21) but also on interferons (in particular STING " stimulator of interferon genes "). The **cellular immunotherapy** emerges as a field of major interest, that it concerns lymphocytes reinjected with chimeric antigen receptor (CARs), or antibodies from tumoral cells. Finally, **microbiota** have also a big interest because the immunogenic bacteria of the intestinal flora could become drug leads in oncology.

The **8th edition of the International R&D Dating** will cover these aspects with the aim to facilitate and stimulate interactions between academic laboratories, networks of clinicians/biologists and industrial partners. The topics will include presentations of the predictive biomarkers of efficiency and side effect, the immunomodulatory and immunocellular control points and therapeutic vaccines, rationalization of combinatorial therapeutic approaches, development and strengthening of preclinical models, new design of clinical trials with regard to the evolutions of standard of care, technological challenges in the control of the bioproduction related to advanced therapy medicinal products.